Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL22
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BL22 is a recombinant anti-CD22 immunotoxin fusion protein composed of a murine anti-CD22 antibody fragment (disulfide-linked Fv, dsFv) fused to a truncated form of *Pseudomonas* exotoxin A (PE38). It specifically binds to CD22-positive cells and is internalized, leading to intracellular release of the toxin. The toxin moiety induces caspase-mediated apoptosis via mitochondrial damage and blocks translational elongation by inactivating elongation factor 2. This results in cell death of malignant B-cells expressing CD22. BL22 was primarily developed for the treatment of chemotherapy-resistant hairy cell leukemia and showed activity in phase I/II trials for this indication. Development was discontinued in favor of moxetumomab pasudotox (HA22), which has improved potency and safety[1][2][3][4].
- Other names
- BL22 immunotoxinBL-22 immunotoxinBL 22 immunotoxinRFB4(dsFv)-PE38
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on BL22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL22.